Abbott’s Xience Skypoint stent. [Image from Abbott]
Abbott executive Dr. Nick West believes the company offers the “best-in-class” drug-eluting stent with its Xience platform.
When Abbott (NYSE:ABT) CMO & divisional VP of global medical affairs Dr. Nick West looks back at his use of drug-eluting stents in the early 2000s, all he sees now is innovation.
As a practicing interventional cardiologist, West remembers an earlier time in which the stents were barely deliverable. Each available platform had marked differences and each had its benefits and drawbacks.
“It’s fair to say that, if you look at the world of drug-eluting stents, they’ve evolved enormously,” West told Drug Delivery Business News. “They’ve just changed hugely.”
Get the full story at our sister site, Drug Delivery Business News.
